Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Danone Buys Wockhardt's Nutrition Brands That Abbott Won Then Lost

This article was originally published in The Tan Sheet

Executive Summary

After several months of discussions, debt-laden Indian drug maker Wockhardt Ltd. managed to sell its growing nutritional business to French food giant Group Danone for a reported $354 million

You may also be interested in...



Emerging Markets Compound Stagnation In Developed Economies

The rapid growth of emerging markets – key regions for many OTC firms – is a major contributor to the industrialized world’s economic stagnation, an HSBC analyst says. Emerging market growth hinders recovery in developed markets by driving up commodity and oil costs, breaking the link in the traditional boom-bust economic cycle.

Emerging Markets Compound Stagnation In Developed Economies

The rapid growth of emerging markets – key regions for many OTC firms – is a major contributor to the industrialized world’s economic stagnation, an HSBC analyst says. Emerging market growth hinders recovery in developed markets by driving up commodity and oil costs, breaking the link in the traditional boom-bust economic cycle.

Signs Point To Abbott Joint Venture With India’s Biocon

India-based Biocon’s collaborative research arm Syngene, known for its research partnerships with a large set of global companies, likely will develop products up to a certain stage based on leads Abbott provides. Industry sources say they expect Abbott and Biocon are in advanced discussions.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel